Solid Biosciences SLDB
NASDAQ SLDB
$7.16 -0.12 (-1.65%)
At close: Sep 29, 2026 · 4:00 PM EDT

Solid Biosciences (SLDB) Operating Margin (2022)

Updated

Solid Biosciences (SLDB) reported Operating Margin of -1315.20% for FY2022, down 784.70 percentage points from -530.50% in FY2021.

Analysis

Solid Biosciences (SLDB) Operating Margin (2022) Analysis & Trends

  • According to Business Quant data, Operating Margin came in at -530.50% in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Operating Margin (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 28.21%
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 37.86%
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn -3.52%
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 32.97%
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 20.57%
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 34.95%
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -133.21%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 28.37%
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 37.40%
10 Solid Biosciences 1.05 Bn 1.05 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 -411.44%
API Access

Solid Biosciences Operating Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-margin&ticker=SLDB&period=max&api_key=YOUR_API_KEY